clarithromycin
E850012
CYP3A4 inhibitor
CYP3A5 inhibitor
CYP3A7 inhibitor
antibacterial drug
macrolide antibiotic
prokinetic agent
Clarithromycin is a macrolide antibiotic commonly used to treat respiratory and other bacterial infections and known for significant drug–drug interactions due to its inhibition of CYP3A4.
Statements (62)
| Predicate | Object |
|---|---|
| instanceOf |
CYP3A4 inhibitor
ⓘ
CYP3A5 inhibitor ⓘ CYP3A7 inhibitor ⓘ antibacterial drug ⓘ macrolide antibiotic ⓘ prokinetic agent ⓘ |
| developedFrom | erythromycin ⓘ |
| hasActiveMetabolite | 14-hydroxyclarithromycin ⓘ |
| hasAntibacterialSpectrum |
Gram-positive bacteria
ⓘ
atypical respiratory pathogens ⓘ some Gram-negative bacteria ⓘ |
| hasATCCode | J01FA09 ⓘ |
| hasBioavailability | about 50% ⓘ |
| hasBrandName |
Biaxin
NERFINISHED
ⓘ
Klacid NERFINISHED ⓘ Klaricid NERFINISHED ⓘ |
| hasCASNumber | 81103-11-9 ⓘ |
| hasChemicalFormula | C38H69NO13 ⓘ |
| hasCommonAdverseEffect |
abdominal pain
ⓘ
diarrhea ⓘ dysgeusia ⓘ gastrointestinal upset ⓘ nausea ⓘ |
| hasContraindication |
concomitant use with certain CYP3A4 substrates that prolong QT interval
ⓘ
history of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use ⓘ |
| hasDosageForm |
extended-release tablet
ⓘ
oral suspension ⓘ tablet ⓘ |
| hasDrugBankID | DB01211 ⓘ |
| hasDrugInteractionType | increases plasma concentrations of CYP3A4 substrates ⓘ |
| hasEliminationHalfLife | 3 to 7 hours ⓘ |
| hasFunctionalGroup |
dimethylamino sugar
ⓘ
macrolide lactone ring ⓘ |
| hasIUPACName | (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-(methoxyimino)-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione ⓘ |
| hasMechanismOfAction | inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit ⓘ |
| hasMolarMass | 747.95 g/mol ⓘ |
| hasProteinBinding | about 70% ⓘ |
| hasRouteOfAdministration |
intravenous
ⓘ
oral ⓘ |
| hasSeriousAdverseEffect |
QT interval prolongation
ⓘ
hepatotoxicity ⓘ torsades de pointes ⓘ |
| hasTarget | bacterial 50S ribosomal subunit ⓘ |
| hasUNII | K8OR5YW8X6 ⓘ |
| inhibits |
CYP3A4
NERFINISHED
ⓘ
P-glycoprotein NERFINISHED ⓘ |
| isExcretedVia |
feces
ⓘ
urine ⓘ |
| isMetabolizedBy | CYP3A4 NERFINISHED ⓘ |
| isOn | World Health Organization Model List of Essential Medicines NERFINISHED ⓘ |
| isPregnancyCategory | Category C (US, historical) ⓘ |
| isSemisyntheticDerivativeOf | erythromycin A NERFINISHED ⓘ |
| isUsedFor |
Helicobacter pylori eradication
ⓘ
Mycobacterium avium complex infections ⓘ acute bacterial exacerbation of chronic bronchitis ⓘ acute maxillary sinusitis ⓘ community-acquired pneumonia ⓘ otitis media ⓘ pharyngitis ⓘ skin and soft tissue infections ⓘ tonsillitis ⓘ |
| wasApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.